Heron Therapeutics Inc vs Waste Management, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Waste Management, Inc. trades at $238.64 (market cap $96.00B). The key difference: Waste Management, Inc. is far larger — about 1049.6× Heron Therapeutics Inc's market cap, and Waste Management, Inc. pays a 1.48% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | WM | |
|---|---|---|
Market Cap | $91.46M | $96.00B |
Sector | Health | Industrials |
52-Week High | $1.96 | $246.51 |
52-Week Low | $0.39 | $196.77 |
Enterprise Value | $189.36M | $118.73B |
Dividend Yield | — | 1.48% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
WM trades at $239.26, showing minimal daily movement with a slight 0.02% decline. The stock maintains a bullish technical outlook with strong moving average signals and trades near its pivot point of $241. Fundamentally, the company demonstrates solid revenue growth from $19.7B in 2022 to $25.2B in 2025, though recent quarters show mixed earnings performance with two misses and one beat against expectations.
WM presents a stable investment case with consistent dividend payments and strong analyst support (57% buy ratings), but faces challenges from elevated debt levels and valuation multiples. The consensus price target of $263.57 suggests 10% upside potential, though investors should monitor execution on earnings guidance and debt management in the coming quarters.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →